Therapeutic Drug Monitoring in Inflammatory Bowel Disease History and Future Directions

被引：16

作者：

Spencer, Elizabeth A. ^{[1
]}

Dubinsky, Marla C. ^{[1
]}

机构：

[1] Icahn Sch Med Mt Sinai, Pediat Gastroenterol & Hepatol, Dept Pediat, Susan & Leonard Feinstein IBD Clin Ctr,Mt Sinai H, 1 Gustave L Levy Pl,Box 1656, New York, NY 10029 USA

来源：

PEDIATRIC CLINICS OF NORTH AMERICA | 2017年 / 64卷 / 06期

关键词：

Inflammatory bowel disease; Therapeutic drug monitoring; Thiopurine metabolite monitoring; Biologics; SEVERE ULCERATIVE-COLITIS; ANTI-TNF THERAPY; THIOPURINE S-METHYLTRANSFERASE; PATIENTS LOSING RESPONSE; INFLIXIMAB TROUGH LEVELS; QUALITY-OF-LIFE; CROHNS-DISEASE; MAINTENANCE THERAPY; PEDIATRIC-PATIENTS; INDUCTION THERAPY;

D O I：

10.1016/j.pcl.2017.08.008

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

Clinical trials for the most effective drugs in the armamentarium of medications for inflammatory bowel disease (IBD) have shown only a 50% to 60% response rate, and this drops to 30% in maintenance. However, therapeutic drug monitoring (TDM) to adjust dosing to account for patient-specific characteristics, which has been shown to improve outcomes, was not used in these trials. This article details the development of TDM within the IBD space as it evolved from thiopurines to biologics and continues to evolve with loftier treat-to-target goals and more sophisticated dashboard systems.

引用

页码：1309 / +

页数：19

共 97 条

[41] Genotyping should be considered the primary choice for pre-treatment evaluation of thiopurine methyltransferase function [J].

Hindorf, Ulf ;

Appell, Malin Lindqvist .

JOURNAL OF CROHNS & COLITIS, 2012, 6 (06) :655-659

[42]

Hyams J, 2007, GASTROENTEROLOGY, V132, pA659

[43] Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children [J].

Hyams, Jeffrey ;

Crandall, Wallace ;

Kugathasan, Subra ;

Griffiths, Anne ;

Olson, Allan ;

Johanns, Jewel ;

Liu, Grace ;

Travers, Suzanne ;

Heuschkel, Robert ;

Markowitz, James ;

Cohen, Stanley ;

Winter, Harland ;

Veereman-Wauters, Gigi ;

Ferry, George ;

Baldassano, Robert .

GASTROENTEROLOGY, 2007, 132 (03) :863-873

[44] Induction and Maintenance Therapy With Infliximab for Children With Moderate to Severe Ulcerative Colitis [J].

Hyams, Jeffrey ;

Damaraju, Lakshmi ;

Blank, Marion ;

Johanns, Jewel ;

Guzzo, Cynthia ;

Winter, Harland S. ;

Kugathasan, Subra ;

Cohen, Stanley ;

Markowitz, James ;

Escher, Johanna C. ;

Veereman-Wauters, Gigi ;

Crandall, Wallace ;

Baldassano, Robert ;

Griffiths, Anne .

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2012, 10 (04) :391-U169

[45] Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease [J].

Hyams, Jeffrey S. ;

Dubinsky, Marla C. ;

Baldassano, Robert N. ;

Colletti, Richard B. ;

Cucchiara, Salvatore ;

Escher, Johanna ;

Faubion, William ;

Fell, John ;

Gold, Benjamin D. ;

Griffiths, Anne ;

Koletzko, Sibylle ;

Kugathasan, Subra ;

Markowitz, James ;

Ruemmele, Frank M. ;

Veereman, Gigi ;

Winter, Harland ;

Masel, Nicholas ;

Shin, Chu Ri ;

Tang, Kezhen L. ;

Thayu, Meena .

GASTROENTEROLOGY, 2017, 152 (08) :1901-+

[46]

Kang Ju-Seop, 2009, Korean Journal of Internal Medicine, V24, P1, DOI 10.3904/kjim.2009.24.1.1

[47] Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response [J].

Katz, Lior ;

Gisbert, Javier P. ;

Manoogian, Beth ;

Lin, Kirk ;

Steenholdt, Casper ;

Mantzaris, Gerassimos J. ;

Atreja, Ashish ;

Ron, Yulia ;

Swaminath, Arun ;

Shah, Somal ;

Hart, Ailsa ;

Lakatos, Peter Laszlo ;

Ellul, Pierre ;

Israeli, Eran ;

Svendsen, Mads Naundrup ;

van der Woude, C. Janneke ;

Katsanos, Konstantinos H. ;

Yun, Laura ;

Tsianos, Epameinondas V. ;

Nathan, Torben ;

Abreu, Maria ;

Dotan, Iris ;

Lashner, Bret ;

Brynskov', Jorn ;

Terdiman, Jonathan P. ;

Higgins, Peter D. R. ;

Chaparro, Maria ;

Ben-Horin, Shomron .

INFLAMMATORY BOWEL DISEASES, 2012, 18 (11) :2026-2033

[48] Thiopurine Metabolite Ratios for Monitoring Therapy in Pediatric Crohn Disease [J].

Kopylov, U. ;

Amre, D. ;

Theoret, Y. ;

Deslandres, C. ;

Seidman, E. G. .

JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2014, 59 (04) :511-515

[49] The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximab [J].

Kopylov, U. ;

Mantzaris, G. J. ;

Katsanos, K. H. ;

Reenaers, C. ;

Ellul, P. ;

Rahier, J. F. ;

Israeli, E. ;

Lakatos, P. L. ;

Fiorino, G. ;

Cesarini, M. ;

Tsianos, E. V. ;

Louis, E. ;

Ben-Horin, S. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 33 (03) :349-357

[50] Routinely Established Skewed Thiopurine Metabolism Leads to a Strikingly High Rate of Early Therapeutic Failure in Patients With Inflammatory Bowel Disease [J].

Kreijne, Joany E. ;

Seinen, Margien L. ;

Wilhelm, Abraham J. ;

Bouma, Gerd ;

Mulder, Chris J. ;

van Bodegraven, Adriaan A. ;

de Boer, Nanne K. H. .

THERAPEUTIC DRUG MONITORING, 2015, 37 (06) :797-804

← 1 2 3 4 5 6 7 8 9 10 →